Juno Therapeutics Overview
Company Headquarters: Washington, US
Founded: 2013
Workforce: ~500 (2016)
Company Working: Juno Therapeutics is a part of Celgene Corporation. It is a biopharmaceutical company formed through the collaboration of Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and pediatrics partner Seattle Children's Research Institute. The company is into the development of cell-based cancer immunotherapies based on chimeric antigen receptor (CAR) and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer. Juno Therapeutics is developing multiple cell-based product candidates to treat a variety of B-cell malignancies as well as multiple solid tumors and multiple myeloma. The company has its offices in the US and Germany. The company has its manufacturing plant in Washington, US.
Strategy
Juno Therapeutics is focused on the usage of human cells as therapeutic entities. It is also investing in scientific research and manufacturing to develop therapies that can treat cancer and other serious diseases more efficiently. The company strives to enhance its product pipeline by adding new therapeutic applications for its potential products.
